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Box lesion or not—Still
unsettled question
To the Editor:
I read with interest the article by Voeller and
associates1 in the April 2008 issue of the
Journal. This is a single center study look-
ing at occurrences of atrial arrhythmias on
follow-up in patients who had the Cox
maze IV procedure with and without box le-
sions. Although the authors have acknowl-
edged several limitations, I would like to
point out another important limitation.
Over 60% of the patients had concomitant
procedures, and a significant proportion of
them had valve operations, which is a signif-
icant confounder for occurrence of postop-
erative atrial arrhythmias. Analysis of the
lone Cox maze IV group would probably of-
fer better insight into the benefit of the box
lesion. However, the numbers seem to be
so small that there may not be adequate
power for this analysis. I will look forward
to any follow-up data in the future from
the authors.
Uma N. Srivatsa, MD
Internal Medicine/Cardiology
University of California—Davis
Sacramento, CA 95670
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Aortic valve replacement
dilemma: mechanical or
biological prosthesis?
To the Editor:
The selection of the appropriate prosthesis
for aortic valve replacement (AVR) is still
open to debate in the case of patients in
the sixth and seventh decades of life.
Recently Brown and colleagues,1 from
Mayo Clinic, reported in the Journal on
an interesting retrospective study about
this topic. By means of patient matching
according to clinical features, they ob-
served in their population a survival advan-
tage after aortic valve replacement with
a mechanical prosthesis relative to a bio-
prosthesis. Brown and colleagues1 stated
that the study was subject to selection
bias and noted that despite case matching
and statistical analysis, surgical bias cannot
be eliminated. Also, in our opinion, it is
virtually impossible to avoid at all biases
and confounding factors in clinical studies.
Nevertheless, the recording of aortic valve
replacement as associated or not with coro-
nary artery bypass grafting simply as a bi-
nary variable could be quite misleading in
drawing conclusions from data analysis.
In fact, age being equal, surgeons could
elect to implant a bioprosthesis rather
than a mechanical valve in patients affected
by more severe coronary artery disease.
Both the extent—isolated single-vessel dis-
ease versus triple-vessel disease—and the
Letters to the EditorReply to the Editor:
My coauthors and I thank Drs Kourliouros,
Roberts, and Jahangiri for their interest in
our recent study.1 We do not disagree with
their suggestion that different statins may
exhibit varying degrees of pleiotropic
effects (eg, anti-inflammatory effects), and
thus believe that their hypothesis that statins
may have differential abilities to prevent
postcardiothoracic surgery (CTS) atrial fi-
brillation is not unreasonable. It is, however,
important to note that the intent of our
nested cohort study was to assess whether
statins as a class are associated with reduc-
tions in post-CTS atrial fibrillation when
used in patients who already have a high
background use of b-blockers (84%) and
appreciable use of prophylactic amiodarone
(44%), rather than to evaluate individual
statins or a dose-response relationship.1
Our primary analysis was worthwhile,
because a large proportion of patients in
ARMYDA-3—the only randomized con-
trolled trial designed to assess the effect of
a statin (atorvastatin at 40 mg/d) on post-
CTS atrial fibrillation as a primary end
point—did not receive b-blockers (arguably
the criterion standard preventative strategy),
and virtually none received prophylactic
amiodarone.2 This treatment pattern likely
explains the high incidence of post-CTS
atrial fibrillation (57%) seen in the AR-
MYDA-3 control group.
Despite the criticism by Kourliouros,
Roberts, and Jahangiri of our dose-response
analysis, we believe that it provides valuable
data to support the claim of a dose-response
effect of statins on post-CTS atrial fibrilla-tion. We would have liked to evaluate
different statins and doses independently;
however, the relatively small number of
patients receiving a statin and the heteroge-
neous uses of different statins and doses
by patients enrolled in the cohort would
have resulted in an underpowered analysis.1
That being said, we applaud the work of
Kourliouros, Roberts, and Jahangiri in con-
ducting an additional analysis to further the
research in this area.3 Ultimately, as Kour-
liouros, Roberts, and Jahangiri suggest, all
nonrandomized studies likely suffer from
some degree of bias or confounding, which
is why a randomized, controlled trial will be
needed to determine definitively whether
different statins exhibit different abilities to
prevent post-CTS atrial fibrillation and
whether dose-response relationships do, in
fact, exist.
Craig Ian Coleman, PharmD
University of Connecticut School of Pharmacy
Storrs, Conn
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